Showing results (11-20 of 464) with videos related to
Sort By:
Pageof 47
Leukemia & Lymphoma|December 16, 2011
Adolescents with Hodgkin lymphoma: old children or young adults?Dennis A Eichenauer, Peter Borchmann, Andreas EngertLeukemia & Lymphoma|June 1, 2016
Current and future immunotherapeutic approaches in Hodgkin lymphomaPaul J Bröckelmann, Peter Borchmann, Andreas EngertNature Reviews. Clinical Oncology|June 13, 2012
State of the art in the treatment of Hodgkin lymphomaPeter Borchmann, Dennis A Eichenauer, Andreas EngertJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2015
Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 TrialsHeinz Haverkamp, Boris Böll, Dennis A Eichenauer, et al.Blood|August 2, 2018
Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Lena Schröder, et al.Leukemia & Lymphoma|December 15, 2005
Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot studySusanne Rödel, Andreas Engert, Volker Diehl, et al.Haematologica|December 7, 2005
Current treatment and immunotherapy of Hodgkin's lymphomaBeate Klimm, Roland Schnell, Volker Diehl, et al.European Journal of Haematology. Supplementum|July 13, 2005
Current treatment strategies of the German Hodgkin Study Group (GHSG)Beate Klimm, Volker Diehl, Beate Pfistner, et al.Current Opinion in Investigational Drugs (London, England : 2000)|January 15, 2005
Monoclonal antibody-based immunotherapy of Hodgkin's lymphomaPeter Borchmann, Roland Schnell, Holger Schulz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2019
Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.Pageof 47